Show simple item record

dc.creatorKovačević, Tijana
dc.creatorVezmar-Kovačević, Sandra
dc.creatorStanetić, Mirko
dc.creatorKovačević, Peđa
dc.creatorMiljković, Branislava
dc.date.accessioned2020-06-03T12:44:04Z
dc.date.available2020-06-03T12:44:04Z
dc.date.issued2020
dc.identifier.issn1078-1552
dc.identifier.urihttp://farfar.pharmacy.bg.ac.rs/handle/123456789/3594
dc.description.abstractBackground: This study aimed to demonstrate that having clinical pharmacist as a member of oncology team in low and middle income countries might lead to significant reduction in the number of erlotinib interactions in the treatment of non-small cell lung cancer patients. Methods: A group of 44 patients was labeled as intervention group and they were analyzed prospectively in the period from 1 January 2017 to 1 May 2018 during clinical pharmacist’s participation in regular weekly multidisciplinary oncology team meetings. The control group consisted of 44 out of 110 patients treated with erlotinib before the involvement of a clinical pharmacist in oncology team, match paired with 44 patients in intervention group. Results: Clinically significant interactions were identified in two-thirds of studied patients (57 out of 88). Most drug interactions, 38%, potentially result in decrease of serum concentration of erlotinib. Clinical pharmacist provided therapy modification suggestions for 32 out of 44 (72.72%) patients in the intervention group, most of which were accepted by doctors. In the intervention group, there were significantly less clinically significant interactions compared to the control group (10 versus 24, p = 0.002). Progression-free survival was significantly longer in the pharmacist’s intervention group (p = 0.001). Conclusions: Clinical pharmacist’s intervention led to significant decrease in erlotinib interactions which may result in treatment optimization of lung cancer patientsen
dc.publisherSAGE Publications Ltd
dc.rightsrestrictedAccess
dc.sourceJournal of Oncology Pharmacy Practice
dc.subjectclinical pharmacist
dc.subjectinteraction
dc.subjectlung cancer
dc.subjectTyrosine kinase inhibitor
dc.titleImpact of pharmacist’s intervention on decreasing erlotinib interactions in the treatment of lung cancer patients in low resource settingsen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractВезмар-Ковачевић, Сандра; Ковачевић, Тијана; Ковачевић, Пеђа; Миљковић, Бранислава; Станетић, Мирко;
dc.citation.rankM23~
dc.identifier.wos000532943500001
dc.identifier.doi10.1177/1078155220921545
dc.identifier.scopus2-s2.0-85084807144
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record